2. Search Result
Search Result
Results for "

Lutetium (177lu) vipivotide tetraxetan

" in MedChemExpress (MCE) Product Catalog:

61

Inhibitors & Agonists

1

Screening Libraries

4

Biochemical Assay Reagents

21

Peptides

3

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117410
    Vipivotide tetraxetan
    Maximum Cited Publications
    17 Publications Verification

    PSMA-617

    		 Drug-Linker Conjugates for ADC Cancer
    Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
    Vipivotide tetraxetan
  • HY-P99239
    Rosopatamab

    HUJ-591; TLX591

    		 PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
    Rosopatamab
  • HY-147057
    Rofapitide tetraxetan
    5+ Cited Publications

    FAP-2286

    		 FAP Cancer
    Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .
    Rofapitide tetraxetan
  • HY-137331
    FAPI-46
    2 Publications Verification

    		 FAP Cancer
    FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted tracer. Use radioactivity FAPI-46 labeled with 68Ga or 177Lu can be used for tumor imaging in a variety of cancers and has higher tumor uptake rates and longer tumor accumulation .
    FAPI-46
  • HY-43869
    Vipivotide tetraxetan Ligand-Linker Conjugate

    PSMA-617 Ligand-Linker Conjugate

    		 ADC Linker Cancer
    Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) .
    Vipivotide tetraxetan Ligand-Linker Conjugate
  • HY-W053583
    Tetraxetan
    1 Publications Verification

    DOTA

    		 Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
    Tetraxetan
  • HY-W1126504
    ETN029

    MC339

    		 Notch Cancer
    ETN029 (MC339) is a selective DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research .
    ETN029
  • HY-100138
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)

    		Radionuclide-Drug Conjugates (RDCs) ADC Linker Cancer
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a metal chelator precursor containing a DOTA macrocyclic structure. DOTA can form highly stable complexes with metal ions (such as 68Ga, 177Lu) through four nitrogen atoms and four carboxylic acid groups to mediate targeted delivery of radionuclides. The tert-butyl ester group (tBu ester) of 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) also protects the carboxylic acid group during synthesis, and forms a free carboxyl group after deprotection reaction for coupling with targeting molecules (such as antibodies, peptides). 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) may be combined with tumor pre-targeting systems through bioorthogonal reactions (such as reverse electron demand Diels-Alder reaction) to study radioactive imaging or therapy of tumor tissues, and is mainly used in tumor pre-targeting research in the field of nuclear medicine .
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)
  • HY-P10944
    Unlabeled FXX489

    NNS309

    		 FAP Inflammation/Immunology Cancer
    Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with 68Ga and 177Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .
    Unlabeled FXX489
  • HY-106033
    Edotreotide
    2 Publications Verification

    DOTATOC; SDZ-SMT 487; SMT 487

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs) .
    Edotreotide
  • HY-P5126
    DOTA-LM3
    2 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-LM3
  • HY-P5128
    DOTA-JR11
    1 Publications Verification

    Satoreotide tetraxetan

    		 Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-JR11
  • HY-P11024
    NVP-EVS459

    		Folate Receptor (FR) Cancer
    NVP-EVS459 is a Folate Receptor (FR)-targeting radioconjugate. NVP-EVS459 labeled with 177Lu can be used for tumor diagnosis and research .
    NVP-EVS459
  • HY-W008951
    Ethylenediaminetetra(methylenephosphonic acid)

    EDTMP

    		 Radionuclide-Drug Conjugates (RDCs) Neurological Disease Cancer
    Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .
    Ethylenediaminetetra(methylenephosphonic acid)
  • HY-P5126A
    DOTA-LM3 TFA
    2 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-LM3 TFA
  • HY-P6825
    PNT2001

    LY4181530; PSMA-62

    		 PSMA Cancer
    PNT2001 (LY4181530) is a potent prostate specific membrane antigen (PSMA) ligand with an IC50 of 3.1 nM. PNT2001 can improve cellular internalization. 177Lu- and 225Ac-labeled PNT2001 can be used in prostate cancer research .
    PNT2001
  • HY-173374
    DOTAGA-FAP-2286-ALB

    		FAP Drug Derivative Cancer
    DOTAGA-FAP-2286-ALB is a derivative of Rofapitide tetraxetan (HY-147057). DOTAGA-FAP-2286-ALB is a selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 67.5 nM. DOTAGA-FAP-2286-ALB enhances tumor retention via albumin interaction, prolonging blood circulation and improving radiometal complex stability (e.g., with 111In and 225Ac). DOTAGA-FAP-2286-ALB is promising for research of radionuclide therapy (TRT) of FAP-positive solid tumors .
    DOTAGA-FAP-2286-ALB
  • HY-P10239
    Tyr3-Octreotate

    		Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs) Cancer
    Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [ 111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [ 90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .
    Tyr3-Octreotate
  • HY-159768A
    DOTAGA.Glu.(FAPi)2

    		Radionuclide-Drug Conjugates (RDCs) FAP Neurological Disease Cancer
    DOTAGA.Glu.(FAPi) 2 is a FAPI homodimer in which a central glutamic acid (Glu) linker connects FAPI and a chelator. Radiolabeled with gallium- 68, lutetium- 177 or terbium- 161, DOTAGA.Glu.(FAPi) 2 is applicable to FAP-positive cancer PET imaging studies. DOTAGA.Glu.(FAPi) 2 is suitable for research related to prostate adenocarcinoma and recurrent glioblastoma multiforme .
    DOTAGA.Glu.(FAPi)2
  • HY-W053583R
    Tetraxetan (Standard)

    DOTA (Standard)

    		 Biochemical Assay Reagents Reference Standards Radionuclide-Drug Conjugates (RDCs) Cancer
    Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
    Tetraxetan (Standard)
  • HY-175613
    DOTA-ALB-02

    		FAP Cancer
    DOTA-ALB-02 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-02 labeled with 177Lu has a high FAP-binding affinity and enhanced tumor uptake and retention with a significant tumor/nontarget ratio. DOTA-ALB-02 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .
    DOTA-ALB-02
  • HY-170779
    DOTA-NI-FAPI-04

    		FAP Cancer
    DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .
    DOTA-NI-FAPI-04
  • HY-164725
    FAPI-mFS

    		Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    FAPI-mFS
  • HY-175744
    PSMA-MAL-5

    		PSMA Cancer
    PSMA-MAL-5 is a PSMA ligand. PSMA-MAL-5 covalently binds to Cys466 of PSMA. PSMA-MAL-5 labeled with 177Lu and 225Ac has high radiostability and tumor uptake. PSMA-MAL-5 also effectively inhibits tumor growth. PSMA-MAL-5 can be used for SPECT/CT imaging and radionuclide therapy of prostate cancer .
    PSMA-MAL-5
  • HY-P10781
    PSMA-D5

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    PSMA-D5 has a binding affinity for PSMA with a Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    PSMA-D5
  • HY-174421
    FAPI-JNU

    		FAP Cancer
    FAPI-JNU is a molecule targeting fibroblast activation protein (FAP). FAPI-JNU specifically binds to FAP highly expressed in the tumor microenvironment, and uses radionuclides [ 68Ga]Ga or [ 177Lu]Lu to achieve tumor imaging diagnosis. [177Lu]Lu−FAPI−JNU can effectively target and inhibit tumor growth in tumor-bearing mice. FAPI-JNU is promising for research of FAP-positive tumors (such as various solid tumors) .
    FAPI-JNU
  • HY-P5297
    DOTA-CXCR4-L

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-CXCR4-L
  • HY-147057A
    Rofapitide tetraxetan acetate

    FAP-2286 acetate

    		 FAP Cancer
    Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .
    Rofapitide tetraxetan acetate
  • HY-P10444
    DOTA Conjugated JM#21 derivative 7

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA Conjugated JM#21 derivative 7
  • HY-139551
    Guraxetan

    		Drug Intermediate Cancer
    Guraxetan can be used for the synthesis of antineoplastic lutetium (177Lu) zadavotide Guraxetan .
    Guraxetan
  • HY-164732
    Fmoc-Lys(DOTA)-OH

    		Amino Acid Derivatives Biochemical Assay Reagents Others
    Fmoc-Lys (DOTA)-OH is an Fmoc-protected Lysine derivative with metal-chelating properties, containing the macrocyclic chelator DOTA. Fmoc-Lys (DOTA)-OH undergoes metallation with Tb or Lu. Fmoc-Lys (DOTA)-OH utilizes metal coordination to protect the carboxyl groups of DOTA. Fmoc-Lys (DOTA)-OH can be used in solid-phase peptide synthesis research .
    Fmoc-Lys(DOTA)-OH
  • HY-175612
    DOTA-ALB-01

    		FAP Cancer
    DOTA-ALB-01 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-01 labeled with 68Ga or 177Lu has a high FAP-binding affinity and enhanced tumor uptake and retention. DOTA-ALB-01 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .
    DOTA-ALB-01
  • HY-164575
    NH2-NODAGA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    NH2-NODAGA is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., 68Ga, 177Lu). NH2-NODAGA can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research .
    NH2-NODAGA
  • HY-173116
    DOTA-XYIMSR-01

    		Carbonic Anhydrase Cancer
    DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy .
    DOTA-XYIMSR-01
  • HY-158266
    DOTA-PSMA-EB-01

    LNC1003

    		 Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-PSMA-EB-01
  • HY-P10743
    BQ7876

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    BQ7876
  • HY-159771
    FAP6-19

    		FAP Cancer
    FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
    FAP6-19
  • HY-P11254
    DOTA-FAPT

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-FAPT is a novel targeting FAP tracer. DOTA-FAPT can be radiolabeled with gallium-68 and lutetium-177. DOTA-FAPT can be used for PET imaging studies of cancer-associated fibroblasts .
    DOTA-FAPT
  • HY-153709
    Zalsenertant tetraxetan

    IPN-01087

    		 Neurokinin Receptor Cancer
    Zalsenertant tetraxetan (IPN-01087) is a DOTA-conjugated antagonist of the neurohypophyseal hormone receptor subtype 1 (NTSR1). Zalsenertant tetraxetan is labeled with the radioactive isotope Lu-177 (177Lu), which can be used for molecular imaging to identify potential responders. Zalsenertant tetraxetan can be used in the radiotherapy research of solid tumors .
    Zalsenertant tetraxetan
  • HY-P10905
    Tezuvotide tetraxetan

    		Peptide-Drug Conjugates (PDCs) Cancer
    Tezuvotide tetraxetan is an antineoplastic peptide .
    Tezuvotide tetraxetan
  • HY-146181
    FSDD1I

    		FAP Cancer
    FSDD1I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD1I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging .
    FSDD1I
  • HY-146180
    FSDD0I

    		FAP Cancer
    FSDD0I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD0I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging .
    FSDD0I
  • HY-146182
    FSDD3I

    		FAP Cancer
    FSDD3I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD3I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging .
    FSDD3I
  • HY-159526
    Adarulatide tetraxetan

    DOTA-AE105

    		 Biochemical Assay Reagents Others
    Copper adarulatidum tetraxetanum (Copper adarulatide tetraxetan) is a diagnostic imaging agent .
    Adarulatide tetraxetan
  • HY-W008951A
    Ethylenediaminetetra(methylenephosphonic acid) sodium

    EDTMP sodium

    		 Radionuclide-Drug Conjugates (RDCs) Neurological Disease Cancer
    Ethylenediaminetetramethylenephosphonic acid (EDTMP) sodium is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid sodium is used to study palliative therapy for pain associated with multiple bone metastatic cancers .
    Ethylenediaminetetra(methylenephosphonic acid) sodium
  • HY-158077
    (R)-tetraMe-Tetraxetan

    (R)-tetraMe-DOTA

    		 Biochemical Assay Reagents Others
    (R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.
    (R)-tetraMe-Tetraxetan
  • HY-P991922
    AKIR001

    		Fc Receptor (FcR) Complement System Radionuclide-Drug Conjugates (RDCs) Cancer
    AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [ 177Lu] radiolabeled AKIR001, namely [ 177Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma .
    AKIR001
  • HY-172150
    XH02

    		Biochemical Assay Reagents Cancer
    XH02 is a compound based on L6 modification. XH02 ( 177Lu labeled) displays exceptional tumor growth inhibition in BxPC-3 tumors .
    XH02
  • HY-P992340
    CTB006

    		Radionuclide-Drug Conjugates (RDCs) TNF Receptor Cancer
    CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .
    CTB006
  • HY-181581
    IMM-H012

    		PI3K Cancer
    IMM-H012 is a specific PI3K inhibitor with an IC50 of 0.80 nM against PI3Kα. IMM-H012 combined with [ 177Lu]Lu-P4 shows synergistic antitumor effects against stomach cancer and lung cancer .
    IMM-H012

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: